Cargando…
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
The goal of the present study was to record changes in bone mineral density (BMD) and markers of bone turnover in patients with rheumatoid arthritis (RA) who were treated with methotrexate combined (or not combined) with infliximab. Included were 90 patients with RA who required anti-TNF-α therapy w...
Autores principales: | Marotte, Hubert, Pallot-Prades, Beatrice, Grange, Laurent, Gaudin, Philippe, Alexandre, Christian, Miossec, Pierre |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206336/ https://www.ncbi.nlm.nih.gov/pubmed/17597527 http://dx.doi.org/10.1186/ar2219 |
Ejemplares similares
-
Shared epitope and rheumatoid arthritis severity: association with infliximab treatment in a postmarketing study
por: Marotte, H, et al.
Publicado: (2003) -
Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
por: Marotte, Hubert, et al.
Publicado: (2008) -
Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients
por: Rinaudo-Gaujous, Mélanie, et al.
Publicado: (2019) -
Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, Hubert, et al.
Publicado: (2005) -
Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, H, et al.
Publicado: (2003)